![Figure 5. SRC assay confirms that M2-MΦs promote expansion of hUCB CD34+ cells ex vivo. (A) Representative flow cytometric charts of analysis of donor-derived human total white blood cells (CD45+), myeloid cells (CD45+CD33+), megakaryocytes (CD45+CD41a+), B cells (CD45+CD19+), and T cells (CD45+CD3+) in BM of the primary (left panel) and secondary (right panel) NSG recipients 4 months after each transplantation. (B) Percentages of human total white blood cells (CD45+), myeloid cells (CD45+CD33+), megakaryocytes (CD45+CD41a+), B cells (CD45+CD19+), and T cells (CD45+CD3+) in BM of the primary NSG recipients. Data are mean ± SEM (n = 17 recipients of three independent transplantations with 3 different units of hUCB CD34+ cell transplants for input and M2-MΦ groups, n = 6 recipients of 1 unit of hUCB CD34+ cell transplant for without [W/O] MΦ group). aP < .05 vs Input, bP < .05 vs W/O MΦ, Mann-Whitney U test. (C) Percentages of human total white blood cells (CD45+), myeloid cells (CD45+CD33+), megakaryocytes (CD45+CD41a+), B cells (CD45+CD19+), and T cells (CD45+CD3+) in BM of the secondary NSG recipients. Data are mean ± SEM (n = 17 for input and M2-MΦ groups, n = 6 for W/O MΦ group). aP < .05 vs Input, bP < .05 vs W/O MΦ, Mann-Whitney U test. (D) Limiting-dilution analysis of the frequency of SRCs in the input CD34+ cells from 2 different units of hUCB cells and the progeny of hUCB CD34+ cells after being cultured with M2-MΦs.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/2/8/10.1182_bloodadvances.2018015685/3/advances015685f5.jpeg?Expires=1724137186&Signature=xdw0r5XxLuUI70CLqzclFPN3-FLp-pVyukIk7tiRC2iMcDUyx~uCBjSshmTSD1HE-psPELACvQYRkEL0~fP5EaIYuFArWRKvzIgB49wazqMbfvRPQGBrUYnJQHZGOgTWVQDqQZfAO04PRIXfsbJlZo2csKfyBsgER0kNbHzVVwfwxzQ86qfVtnNWrBBOlWL7afhZCjAVEBsUUZfBpM6irnTqI5gxkBgIVgXAOE~0eUZDjHZUbmE2GOMY63e7PVNVbFhRrU7szLp-4efsnqfZnu9IRHRoCw4C4XdqGjrAAP75HRn9m~cBHsNB4TXur1p4XCHdwRjv8R1WLQcjNs-1DA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
SRC assay confirms that M2-MΦs promote expansion of hUCB CD34+cells ex vivo. (A) Representative flow cytometric charts of analysis of donor-derived human total white blood cells (CD45+), myeloid cells (CD45+CD33+), megakaryocytes (CD45+CD41a+), B cells (CD45+CD19+), and T cells (CD45+CD3+) in BM of the primary (left panel) and secondary (right panel) NSG recipients 4 months after each transplantation. (B) Percentages of human total white blood cells (CD45+), myeloid cells (CD45+CD33+), megakaryocytes (CD45+CD41a+), B cells (CD45+CD19+), and T cells (CD45+CD3+) in BM of the primary NSG recipients. Data are mean ± SEM (n = 17 recipients of three independent transplantations with 3 different units of hUCB CD34+ cell transplants for input and M2-MΦ groups, n = 6 recipients of 1 unit of hUCB CD34+ cell transplant for without [W/O] MΦ group). aP < .05 vs Input, bP < .05 vs W/O MΦ, Mann-Whitney U test. (C) Percentages of human total white blood cells (CD45+), myeloid cells (CD45+CD33+), megakaryocytes (CD45+CD41a+), B cells (CD45+CD19+), and T cells (CD45+CD3+) in BM of the secondary NSG recipients. Data are mean ± SEM (n = 17 for input and M2-MΦ groups, n = 6 for W/O MΦ group). aP < .05 vs Input, bP < .05 vs W/O MΦ, Mann-Whitney U test. (D) Limiting-dilution analysis of the frequency of SRCs in the input CD34+ cells from 2 different units of hUCB cells and the progeny of hUCB CD34+ cells after being cultured with M2-MΦs.
